

# Aesthetic Plastic Surgery Practice Offers the First and Only FDA-approved Injectable for Cellulite

DOVER, OHIO, UNITED STATES, October 26, 2021 /EINPresswire.com/ -- Fine Arts Skin & Laser, a boutique aesthetic plastic surgery practice and med spa, is now offering QWO, the only FDA-approved injectable treatment for cellulite.

QWO is a non-surgical treatment used to treat moderate to severe cellulite in the buttocks of adult women. Injections take less than ten minutes and include three treatments over the course of 6 weeks. QWO has been studied on all skin types and ethnicities.

"A lot of women deal with cellulite," says Dr. David Hartman, owner of [Fine Arts Skin and Laser](#), "Boosting a patient's confidence with their body image is a highlight of my job and this product allows us to go above and beyond with results."



The enzymes in QWO are believed to target a structural cause under the skin. It is thought that QWO works in 3 ways: by releasing fibrous bands, redistributing fat cells, and stimulating growth of new collagen.

[Book a Consultation](#) with Dr. Hartman.

\*\*\*

About Fine Arts Skin & Laser

Dr. David Hartman is a double board-certified facial plastic and reconstructive surgeon in northeast Ohio and owner of Fine Arts Skin & Laser, a boutique aesthetic plastic surgery practice and med spa. Their practice specializes in high-definition body sculpting and natural-looking facelifts and eyelid rejuvenation. Fine Arts also provides world-class esthetician services. Dr.

Hartman is certified by both the American Board of Facial Plastic and Reconstructive Surgery, and the American Board of Otolaryngology-Head & Neck Surgery. He is a fellow of the American College of Surgeons (FACS), and the American Medical Association, and a member of the American Academy of Regenerative Medicine, the American Academy of Cosmetic Surgery, the International Society of Cosmetic Surgery, and the American Medical Association.

###

Emily Bensi  
Bowers PR & Marketing  
+1 740-815-8333  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/554723775>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.